Abstract

Altered hepatic glucose fluxes are critical during the pathogenesis of type 2 diabetes. G protein-coupled receptors represent important regulators of hepatic glucose production. Recent studies have shown that hepatocytes express GPCRs that can couple to G12/13, a subfamily of heterotrimeric G proteins that has attracted relatively little attention in the past. Here we show, by analyzing several mutant mouse strains, that selective activation of hepatocyte G12/13 signaling leads to pronounced hyperglycemia and that this effect involves the stimulation of the ROCK1-JNK signaling cascade. Using both mouse and human hepatocytes, we also show that activation of endogenous sphingosine-1-phosphate type 1 receptors strongly promotes glucose release in a G12/13-dependent fashion. Studies with human liver samples indicate that hepatic GNA12 (encoding Gα12) expression levels positively correlate with indices of insulin resistance and impaired glucose homeostasis, consistent with a potential pathophysiological role of enhanced hepatic G12/13 signaling.

Altered hepatic glucose fluxes play a key role in the pathogenesis of type 2 diabetes. Here, Pittala et al. show that activation of G12/13 signaling in hepatocytes enhances hepatic glucose production, leading to greatly increased blood glucose levels.

Details

Title
G12/13-mediated signaling stimulates hepatic glucose production and has a major impact on whole body glucose homeostasis
Author
Pittala, Srinivas 1   VIAFID ORCID Logo  ; Haspula, Dhanush 1 ; Cui, Yinghong 1 ; Yang, Won-Mo 2   VIAFID ORCID Logo  ; Kim, Young-Bum 2   VIAFID ORCID Logo  ; Davis, Roger J. 3   VIAFID ORCID Logo  ; Wing, Allison 4   VIAFID ORCID Logo  ; Rotman, Yaron 4   VIAFID ORCID Logo  ; McGuinness, Owen P. 5   VIAFID ORCID Logo  ; Inoue, Asuka 6   VIAFID ORCID Logo  ; Wess, Jürgen 1   VIAFID ORCID Logo 

 NIH, Molecular Signaling Section, Laboratory of Bioorganic Chemistry, NIDDK, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547) 
 University of Massachusetts Chan Medical School, Program in Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364) 
 NIH, Liver & Energy Metabolism Section, Liver Diseases Branch, NIDDK, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
 Vanderbilt University School of Medicine Basic Sciences, Departments of Molecular Physiology and Biophysics, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217) 
 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033) 
Pages
9996
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3129868808
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.